--- title: "Indaptus Therapeutics (INDP) news: reverse split and offering" url: "https://aibio.space/companies/indaptus-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "INDP reverse split and offering news: Indaptus stockholders approve preferred stock conversion and reverse split range. Indaptus Therapeutics, Inc." --- INDP Indaptus Therapeutics, Inc. NASDAQ · United States # Indaptus Therapeutics (INDP) news INDP reverse split and offering news Financings · 2026-10-20 ## [Indaptus Therapeutics closes $24.0 million private placement of 20,338,974 shares](https://aibio.space/news/indaptus-therapeutics-closes-24-0-million-private-placement-20-338-974/) Indaptus sold 20,338,974 shares for approximately $24.0 million after the closing date was pushed back. Its cash was $7.6 million at June 30, 2026, and its 2025 net loss was $20.8 million. ## Latest Indaptus Therapeutics news 1. 2026-03-24 Mergers [Indaptus Therapeutics reports change in control as Lazar sells preferred stock for $11,200,000](https://aibio.space/news/indaptus-therapeutics-reports-change-control-lazar-sells-preferred/) Five buyers including Yun Yao and Sino Lion Ventures Limited bought preferred stock that could convert into 108,936,000 shares. The board appointed Junyi Dai chairman and chief executive officer, and four directors resigned on March 18, 2026. 2. 2026-02-27 Mergers [Indaptus stockholders approve preferred stock conversion and reverse split range](https://aibio.space/news/indaptus-stockholders-approve-preferred-stock-conversion-reverse-split/) Stockholders approved conversion of preferred stock that, once converted, would give David Lazar 111.0 million common shares, about 96.4% of the fully diluted common stock. They also approved up to two reverse stock splits and authorized shares rising to 1,000,000,000. 3. 2025-07-16 Listings [Indaptus Therapeutics regains Nasdaq compliance with $1.00 bid price rule](https://aibio.space/news/indaptus-therapeutics-regains-nasdaq-compliance-1-00-bid-price-rule/) The stock closed at $1.00 or higher for 10 consecutive business days from June 27, 2025 to July 11, 2025. Nasdaq considers the matter closed. ## Indaptus Therapeutics at a glance - **Ticker**: INDP - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $11.6 million ### Related companies - [Puma Biotechnology](https://aibio.space/companies/puma-biotechnology/) NASDAQ: PBYI - [Xilio Therapeutics](https://aibio.space/companies/xilio-therapeutics/) NASDAQ: XLO - [Phathom Pharmaceuticals](https://aibio.space/companies/phathom-pharmaceuticals/) NASDAQ: PHAT - [Supernus Pharmaceuticals](https://aibio.space/companies/supernus-pharmaceuticals/) NASDAQ: SUPN - [Pacira BioSciences](https://aibio.space/companies/pacira-biosciences/) NASDAQ: PCRX - [Reviva Pharmaceuticals Holdings](https://aibio.space/companies/reviva-pharmaceuticals/) OTC: RVPH - [Lipella Pharmaceuticals](https://aibio.space/companies/lipella-pharmaceuticals/) OTC: LIPO - [Prestige Consumer Healthcare](https://aibio.space/companies/prestige-consumer-healthcare/) NYSE: PBH ### Also on NASDAQ - [BIOLIFE SOLUTIONS INC](https://aibio.space/companies/biolife-solutions/) BLFS - [IceCure Medical](https://aibio.space/companies/icecure-medical/) ICCM - [Jupiter Neurosciences](https://aibio.space/companies/jupiter-neurosciences/) JUNS - [Clearmind Medicine](https://aibio.space/companies/clearmind-medicine/) CMND - [Skye Bioscience](https://aibio.space/companies/skye-bioscience/) SKYE - [Eikon Therapeutics](https://aibio.space/companies/eikon-therapeutics/) EIKN ## Indaptus Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$9.3 million](https://www.sec.gov/Archives/edgar/data/1857044/000149315226010585/) | [$7.3 million](https://www.sec.gov/Archives/edgar/data/1857044/000149315226010585/) | | Net income (loss) | [-$20.8 million](https://www.sec.gov/Archives/edgar/data/1857044/000149315226010585/) | [-$15.0 million](https://www.sec.gov/Archives/edgar/data/1857044/000149315226010585/) | | Cash from operations | [-$14.8 million](https://www.sec.gov/Archives/edgar/data/1857044/000149315226010585/) | [-$12.3 million](https://www.sec.gov/Archives/edgar/data/1857044/000149315226010585/) | | Cash and equivalents | [$8.5 million](https://www.sec.gov/Archives/edgar/data/1857044/000149315226037579/) | [$5.8 million](https://www.sec.gov/Archives/edgar/data/1857044/000149315226010585/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $7.6 million, plus short-term investments of $4.0 million, $11.6 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Indaptus Therapeutics Did Indaptus Therapeutics do a reverse stock split? Our latest story on this, dated Feb 27, 2026: "Indaptus stockholders approve preferred stock conversion and reverse split range". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/indaptus-stockholders-approve-preferred-stock-conversion-reverse-split/). Has Indaptus Therapeutics raised money recently? Our latest story on this, dated Oct 20, 2026: "Indaptus Therapeutics closes $24.0 million private placement of 20,338,974 shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/indaptus-therapeutics-closes-24-0-million-private-placement-20-338-974/). What is the ticker symbol of Indaptus Therapeutics? Indaptus Therapeutics, Inc. trades under the ticker INDP on NASDAQ. Where is Indaptus Therapeutics listed? Indaptus Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Indaptus Therapeutics? The SEC Central Index Key (CIK) for Indaptus Therapeutics, Inc. is 1857044. Its filings are on SEC EDGAR. How many shares does Indaptus Therapeutics have outstanding? 133,242,324 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Indaptus Therapeutics listed under? Our directory records Indaptus Therapeutics, Inc. under United States. What does Indaptus Therapeutics do? Our directory classifies Indaptus Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Indaptus Therapeutics? The ISIN recorded for Indaptus Therapeutics, Inc. is US45339J2042. Does aibio.space cover Indaptus Therapeutics? aibio.space lists Indaptus Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Indaptus Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Indaptus Therapeutics profitable? Indaptus Therapeutics, Inc. reported a net loss of $20.8 million for the fiscal year ended Dec 31, 2025, and used $14.8 million of cash in operations, per its annual report to the SEC. How much does Indaptus Therapeutics spend on research and development? $9.3 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Indaptus Therapeutics have? $11.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Indaptus Therapeutics (INDP) stock news? Our latest story on Indaptus Therapeutics, dated Oct 20, 2026: "Indaptus Therapeutics closes $24.0 million private placement of 20,338,974 shares". Indaptus sold 20,338,974 shares for approximately $24.0 million after the closing date was pushed back. Its cash was $7.6 million at June 30, 2026, and its 2025 net loss was $20.8 million. [Source](https://aibio.space/news/indaptus-therapeutics-closes-24-0-million-private-placement-20-338-974/). ## Investor discussion: Indaptus Therapeutics Members talk about Indaptus Therapeutics (INDP). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Indaptus Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-20 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1857044/000149315226047770/form8-k.htm) 2. 2026-09-30 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1857044/000149315226045040/form8-k.htm) 3. 2026-08-31 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1857044/000149315226040751/form424b5.htm) 4. 2026-08-17 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1857044/000149315226038780/forms-3.htm) 5. 2026-06-24 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1857044/000149315226029918/0001493152-26-029918-index-headers.html) 6. 2026-02-27 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.01,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1857044/000149315226008326/form8-k.htm) 7. 2026-02-12 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1857044/000149315226006330/form8-k.htm) 8. 2026-01-21 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1857044/000149315226003135/formdef14a.htm) 9. 2026-01-08 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1857044/000149315226000999/formpre14a.htm) 10. 2025-12-23 Listings Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,3.03,5.02,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1857044/000149315225029107/form8-k.htm) 11. 2025-07-29 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,5.07). [Source](https://www.sec.gov/Archives/edgar/data/1857044/000164117225021377/form8-k.htm) 12. 2025-07-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1857044/000164117225019893/form8-k.htm) 13. 2025-06-26 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1857044/000164117225016694/ex99-1.htm) 14. 2025-06-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1857044/000164117225014972/ex99-1.htm) 15. 2025-06-11 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1857044/000164117225014689/form8-k.htm) 16. 2025-04-28 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1857044/000164117225006429/formdef14a.htm) 17. 2025-04-17 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1857044/000164117225005234/formpre14a.htm) 18. 2025-02-12 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1857044/000149315225006052/form8-k.htm) 19. 2025-01-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1857044/000149315225004428/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:INDP on TradingView](https://www.tradingview.com/symbols/NASDAQ-INDP/). ## SEC filings and registration - **SEC name**: Indaptus Therapeutics, Inc. - **CIK**: 1857044 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: INDP (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 3 COLUMBUS CIRCLE, NEW YORK, NY, 10019 - **Phone**: (646) 427-2727 - **Shares outstanding**: 133,242,324 as of 2026-08-13 (10-Q filed 2026-08-13) - **Former names**: Intec Parent Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1857044/000149315226047770/form8-k.htm) filed 2026-10-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1857044/000149315226045040/form8-k.htm) filed 2026-09-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1857044/000149315226042037/form8-k.htm) filed 2026-09-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1857044/000149315226041532/form8-k.htm) filed 2026-09-04 - [424B5](https://www.sec.gov/Archives/edgar/data/1857044/000149315226041526/form424b5.htm) filed 2026-09-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1857044/000149315226040926/form8-k.htm) filed 2026-09-01 - [424B5](https://www.sec.gov/Archives/edgar/data/1857044/000149315226040751/form424b5.htm) filed 2026-08-31 - [S-3](https://www.sec.gov/Archives/edgar/data/1857044/000149315226038780/forms-3.htm) filed 2026-08-17 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001857044), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Indaptus Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker INDP, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Indaptus Therapeutics, Inc. - **Ticker**: INDP - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US45339J2042 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-INDP/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/indaptus-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Indaptus Therapeutics (INDP) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/indaptus-therapeutics/